Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Chest

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.chest.2016.08.1462PMID 27637548PMCID PMC5310120
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.

  2016cited by this paper
• An Assessment of the State of Current Practice in Coagulation Laboratories.

  2016cited by this paper
• Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum

  2016cited by this paper
• Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.

  2015cited by this paper
• Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.

  2015cited by this paper
• Multimodal assessment of non‐specific hemostatic agents for apixaban reversal

  2015cited by this paper
• Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban

  2015cited by this paper
• Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples

  2015cited by this paper
• The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

  2015cited by this paper
• How the direct oral anticoagulant apixaban affects thrombin generation parameters.

  2015cited by this paper
• Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

  2015cited by this paper
• Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome

  2015cited by this paper
• Assessing the anticoagulant effect of dabigatran in children: an in vitro study.

  2015cited by this paper
• Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.

  2015cited by this paper
• Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.

  2015cited by this paper
• Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban

  2015cited by this paper
• Measurement of Non–Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method

  2015cited by this paper
• Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.

  2015cited by this paper
• Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban

  2015cited by this paper
• Comparison of methods to determine rivaroxaban anti-factor Xa activity.

  2015cited by this paper
• Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.

  2015cited by this paper
• Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real–Life” Patients With Atrial Fibrillation

  2015cited by this paper
• Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review

  2015cited by this paper
• Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.

  2014cited by this paper
• Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests

  2014cited by this paper
• Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents

  2014cited by this paper
• Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban

  2014cited by this paper
• Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

  2014cited by this paper
• The in-vitro anticoagulant effect of rivaroxaban in neonates

  2014cited by this paper
• Estimation of dabigatran plasma concentrations in the perioperative setting

  2014cited by this paper
• Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.

  2014cited by this paper
• Influence of dabigatran and rivaroxaban on routine coagulation assays

  2014cited by this paper
• Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban

  2014cited by this paper
• On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.

  2014cited by this paper
• Performance of coagulation tests in patients on therapeutic doses of rivaroxaban

  2014cited by this paper
• Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF

  2014cited by this paper
• A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

  2014cited by this paper
• An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis

  2014cited by this paper
• Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran.

  2014cited by this paper
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

  2014cited by this paper
• Laboratory testing for the new oral anticoagulants: a review of current practice.

  2013cited by this paper
• Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma

  2013cited by this paper
• Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate

  2013cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

  2013cited by this paper
• Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.

  2013cited by this paper
• Preincubation in the Prothrombinase‐induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban

  2013cited by this paper
• A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants.

  2013cited by this paper
• Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels

  2013cited by this paper
• In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban

  2013cited by this paper
• A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors

  2013cited by this paper
• In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban

  2013cited by this paper
• Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.

  2013cited by this paper
• A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.

  2013cited by this paper
• Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

  2013cited by this paper
• Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay

  2013cited by this paper
• Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays

  2013cited by this paper
• Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban

  2013cited by this paper
• Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

  2012cited by this paper
• Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study

  2012cited by this paper
• UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.

  2012cited by this paper
• Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.

  2012cited by this paper
• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.

  2012cited by this paper
• Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls

  2012cited by this paper
• Determination of Dabigatran in Human Plasma Samples

  2012cited by this paper
• Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

  2012cited by this paper
• Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests

  2012cited by this paper
• Impact of dabigatran on a large panel of routine or specific coagulation assays

  2012cited by this paper
• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation

  2012cited by this paper
• Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.

  2012cited by this paper
• The in vitro anticoagulant effect of rivaroxaban in children.

  2012cited by this paper
• Interpretation of point-of-care INR results in patients treated with dabigatran.

  2012cited by this paper
• Dabigatran: laboratory monitoring.

  2012cited by this paper
• Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.

  2012cited by this paper
• In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

  2012cited by this paper
• Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin

  2012cited by this paper
• Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma

  2011cited by this paper
• Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor

  2011cited by this paper
• Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

  2011cited by this paper
• Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls

  2011cited by this paper
• Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

  2011cited by this paper
• Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

  2011cited by this paper
• Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Erratum to: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention

  2011cited by this paper
• Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

  2011cited by this paper
• Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

  2011cited by this paper
• Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate

  2011cited by this paper
• The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban‐treated patients: results of an in vitro study

  2011cited by this paper
• Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system

  2011cited by this paper
• Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban

  2011cited by this paper
• Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

  2010cited by this paper
• Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

  2010cited by this paper
• Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

  2010cited by this paper
• Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays

  2010cited by this paper
• Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

  2010cited by this paper

• An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.

  2026cites this paper
• Utilization of Apixaban Pharmacokinetics for Dose Optimization in High-Risk Elderly Patients.

  2026cites this paper
• Ischemic Stroke in Patients Under Oral Anticoagulation: The Achilles Heel of Atrial Fibrillation Management

  2025cites this paper
• Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage

  2025cites this paper
• [Management of emergencies in direct oral anticoagulant-treated patients: practice pearls].

  2025cites this paper
• Application of multigene panel testing for bleeding, thrombotic, and platelet disorders in patients and the general population in China

  2025cites this paper
• A Novel Integrated Strategy for Discovering Absorbable Anticoagulant Bioactive Peptides: A Case Study on Leech Protein Hydrolysates

  2025cites this paper
• A Pilot Study to Evaluate an International Normalized Ratio-Derived Formula in Combination with Heparin-Calibrated Anti-Xa Activity in Calculating a Plasma Edoxaban Level

  2025cites this paper
• Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients

  2025cites this paper
• How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation.

  2025cites this paper
• Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

  2025cites this paper
• Enhancing vascular implants with heparin-polylysine-copper nanozyme coating for synergistic anticoagulation and antirestenotic activity.

  2025cites this paper
• Anticoagulation Failure in Stroke: Causes, Risk Factors, and Treatment

  2025cites this paper
• Direct Oral Anticoagulant Transition Strategies Using Anti-Xa Concentrations Upon Intensive Care Unit Admission

  2025cites this paper
• A comprehensive verification approach of coagulation analyser, analytical performance of the sysmex CS-2500.

  2025cites this paper
• Biosynthesis of novel anticoagulant substances, α-salicin and α-isosalicin, using sucrose phosphorylase.

  2025cites this paper
• Direkte orale Antikoagulanzien: Was kann die Labordiagnostik aktuell leisten?

  2025cites this paper
• Padua Score and D-dimer for Pulmonary Embolism Exclusion in the Elderly

  2025cites this paper
• Effect of concurrent use of rivaroxaban or apixaban with amiodarone on international normalised ratio: a retrospective observational study.

  2025cites this paper
• Comparative Safety of Tenecteplase and Alteplase in Direct Oral Anticoagulant‐Pretreated Patients With Acute Ischemic Stroke

  2025cites this paper
• Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI - A Secondary Analysis of a Multicenter Randomized Controlled Trial.

  2025cites this paper
• Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs

  2024cites this paper
• Effect of extraction method on the structure and bioactivity of polysaccharides from activated sludge.

  2024cites this paper
• DOACs: role of anti-Xa and drug level monitoring.

  2024cites this paper
• Nomogram for predicting bleeding events in nonvalvular atrial fibrillation patients receiving rivaroxaban: A retrospective study

  2024cites this paper
• Thromboembolic prevention in athletes: management of anticoagulation in sports players affected by atrial fibrillation

  2024cites this paper
• 臨床現場における薬剤師の役割（13）

  2024cites this paper
• International Normalized Ratio Predicts Recurrence and Bleeding in Patients With Acute Venous Thromboembolism Who Undergo Direct Oral Anticoagulants

  2024cites this paper
• Intravenous thrombolysis and mechanical thrombectomy in acute stroke patients on direct oral anticoagulants

  2024cites this paper
• RETRACTED ARTICLE: Effect of Danhong injection on pharmacokinetics and pharmacodynamics of rivaroxaban in rats

  2024cites this paper
• LTSI Consensus Guidelines: Preoperative Cardiac Evaluation in Adult Liver Transplant Recipients.

  2024cites this paper
• Management of severe traumatic brain injury in a rivaroxaban overdose: illustrative case

  2024cites this paper
• Time-Dependent Association of Preinjury Anticoagulation on Traumatic Brain Injury-Induced Coagulopathy: A Retrospective, Multicenter Cohort Study

  2024cites this paper
• Clinical Care Pathway and Management of Major Bleeding Associated with Nonvitamin K Antagonist Oral Anticoagulants: A Modified Delphi Consensus from Saudi Arabia and UAE

  2024cites this paper
• Pulmonary embolism in cancer patients. Effectiveness of vitamin K antagonists and direct oral anticoagulants in long-term therapy

  2024cites this paper
• Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants

  2024influential citation
• Intra-Individual Variability of Direct Oral Anticoagulant Levels in Frail Older Patients Upon, During, and After Acute Hospitalization: the DOAC-FRAIL Study.

  2024cites this paper
• 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP

  2024cites this paper
• 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP

  2024cites this paper
• Multidisciplinary Expert Guidance for the Management of Severe Bleeding on Oral Anticoagulation: An Algorithm for Practicing Clinicians

  2024influential citation
• The 2023 WSES guidelines on the management of trauma in elderly and frail patients

  2024cites this paper
• 2024 EACTS Guidelines on perioperative medication in adult cardiac surgery.

  2024cites this paper
• Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation

  2024cites this paper
• Anticoagulation in Pediatric Patients.

  2024cites this paper
• Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

  2024cites this paper
• Assessing Direct Oral Anticoagulants in the Clinical Laboratory.

  2024cites this paper
• Thrombolysis for Ischemic Stroke Despite Recent Ingestion of Direct Oral Anticoagulants – A Growing Dilemma Also in India

  2024cites this paper
• A Narrative Review on Central Neuraxial Blocks and Direct Oral Anticoagulants

  2024cites this paper
• Detection of direct oral anticoagulants with the diluted Russel's viper venom time

  2024cites this paper
• Coagulation Tests and Reversal Agents in Patients Treated with Oral Anticoagulants: The Challenging Scenarios of Life-Threatening Bleeding and Unplanned Invasive Procedures

  2024cites this paper
• 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP.

  2024cites this paper
• Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours.

  2024cites this paper
• Acute compartment syndrome following biceps tendon rupture: a case report

  2024cites this paper
• Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing

  2024cites this paper
• Peak plasma anti-Xa direct oral anticoagulant levels after gastrointestinal surgeries: A retrospective cohort.

  2024cites this paper
• ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events

  2024cites this paper
• Direct oral anticoagulants in trauma patients

  2024cites this paper
• The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases

  2024cites this paper
• Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?

  2024cites this paper
• Development of Machine-learning Model to Predict Anticoagulant Use and Type in Geriatric Traumatic Brain Injury Using Coagulation Parameters

  2024cites this paper
• Pharmacologie clinique comparée des anticoagulants oraux : antivitamine K et anticoagulants oraux directs

  2023cites this paper
• Poor Correlation of Rivaroxaban Concentration with the Routine Coagulation Screening Test in Chinese Patients with Atrial Fibrillation

  2023cites this paper
• Thrombin generation, bleeding and hemostasis in humans: Protocol for a scoping review of the literature

  2023cites this paper
• In Silico, In Vitro, and In Vivo Evaluation of Caffeine-Coated Nanoparticles as a Promising Therapeutic Avenue for AML through NF-Kappa B and TRAIL Pathways Modulation

  2023cites this paper
• Evidence-based Management of Major Bleeding in Patients Receiving Direct Oral Anticoagulants: An Updated Narrative Review on the Role of Specific Reversal Agents

  2023cites this paper
• Reversal agents for current and forthcoming direct oral anticoagulants.

  2023cites this paper
• Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants.

  2023cites this paper
• Assessment of coagulation assays on Roche Cobas t711 analyzer: performance and clinical implications

  2023cites this paper
• Farmacología clínica comparada de los anticoagulantes orales: antivitamínicos K y anticoagulantes orales directos

  2023cites this paper
• An update on applications and limitations of direct oral anticoagulants

  2023cites this paper
• Safety and efficacy of oral anticoagulants in extreme weights.

  2023cites this paper
• Effective Prevention of Arterial Thrombosis with Albumin-Thrombin Inhibitor Conjugates.

  2023cites this paper
• Bleeding management in patients with direct oral anticoagulants.

  2023cites this paper
• Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding.

  2023cites this paper
• Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information

  2023cites this paper
• To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice

  2023cites this paper
• Coumarin functionalized dimeric mesogens for promising anticoagulant activity: Tuning of liquid crystalline property

  2023cites this paper
• Bleeding on oral anticoagulants: overview of reversal strategies.

  2023cites this paper
• [Proper use of oral anticoagulants in the elderly patient].

  2023cites this paper
• Stability of Rivaroxaban and Apixaban Anti-Xa Activities in Whole Blood Samples: A French Bicentric Study

  2023cites this paper
• Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness

  2023influential citation
• Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis

  2023cites this paper
• Continuous use of antithrombotic medications during peri‐endoscopic submucosal dissection period for colorectal lesions: A propensity score matched study

  2023cites this paper
• How I Treat: The approach to Prevention and Treatment of Thrombotic Complications in Hospitalized Patients.

  2023cites this paper
• Acquired Hemophilia A Masquerading as Bleeding on Anticoagulation: A Case Report Including Key Laboratory Considerations

  2023cites this paper
• EFFECT OF ANTICOAGULANT TREATMENT OF DABIGATRAN AND WARFARIN ON HEMOSTASIS IN PATIENTS WITH LIVER CIRRHOSIS AND ATRIAL FIBRILATION.

  2022cites this paper
• Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients

  2022cites this paper
• Bleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors

  2022cites this paper
• Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study

  2022cites this paper
• Anticoagulation Monitoring in the Intensive Care Unit

  2022cites this paper
• Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort

  2022cites this paper
• Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.

  2022cites this paper
• Recommendations from the ICM-VTE: General.

  2022cites this paper
• Use of Prothrombin Complex Concentrate in Oral Anticoagulant-Associated Major Bleeding

  2022cites this paper
• Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.

  2022cites this paper
• How to handle a delayed or missed dose of edoxaban in patients with non‐valvular atrial fibrillation? A model‐informed remedial strategy

  2022cites this paper
• Direct Oral Anticoagulants: Laboratory Challenges and Antidotes

  2022cites this paper
• Anticoagulants in Trauma

  2022cites this paper
• DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature.

  2022cites this paper
• Apixaban and Rivaroxaban Anti-Xa Concentration Utilization in Clinical Practice

  2022cites this paper